Paul Herrling

Prof. Paul Herrling is Head of Corporate Research at Novartis, a position he assumed in November 2002. He is also Chairman of the Board of the newly created Novartis Institute for Tropical Diseases in Singapore, a long-term endeavor to advance medical research in the area of progessive infectious diseases, which historically have received little funding. 

Prof. Herrling also oversees the Friedrich Miescher Institute in Basel, Switzerland, and serves on the board of the Genomics Institute of the Novartis Research Foundation in La Jolla, California as well as on the boards of several other research institutions. 

Prior to his current position, Paul Herrling was Head of Global Research at Novartis Pharma and a member of the Pharma Executive Committee (PEC). In this capacity, he directed the integration of the research organisations of Sandoz and Ciba-Geigy following their merger in 1996 to form Novartis, and he established many of the elements of the Group’s new research strategy. 

Prof. Herrling joined Sandoz Pharma in 1975 and held various positions in research at both Sandoz in Basel and Wander in Bern. In 1985, he became the Head of the Sandoz Research Institute Berne and Head of the Preclinical CNS Research Department at Sandoz Pharma in Basel. In 1992, he was made Head of Preclinical Research Basel for Sandoz Pharma and, in 1994, Head of Corporate Research. 

Paul Herrling is also Professor of Drug Discovery Science at the University of Basel, Switzerland and Full Adjunct Professor at the Harold Dorris Neurobiological Institute, Scripps Research Institut, La Jolla, Califonia. He obtained his doctorate in 1975 at the University of Zurich and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA). 

In addition to a number of scientific editing activities, he serves on several boards, most notably: the Board of Trustees Novartis Foundation, London, the Board of Trustees Fondation Maison de la Chimie, Paris. He is also Director of Chiron, Emoryville, California, and of the TSRI-Novartis Joint Scientific Council, La Jolla.